Compare CMRE & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMRE | CRVS |
|---|---|---|
| Founded | 1974 | 2014 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | N/A | 2016 |
| Metric | CMRE | CRVS |
|---|---|---|
| Price | $17.19 | $16.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $28.00 |
| AVG Volume (30 Days) | 462.9K | ★ 2.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.63 | $2.54 |
| 52 Week High | $17.52 | $26.95 |
| Indicator | CMRE | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 56.04 | 48.45 |
| Support Level | $16.62 | $17.27 |
| Resistance Level | $17.52 | $19.98 |
| Average True Range (ATR) | 0.63 | 1.29 |
| MACD | 0.04 | -0.83 |
| Stochastic Oscillator | 68.05 | 0.00 |
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).